What Acera Surgical does

Acera Surgical is a St. Louis-based bioscience company founded in 2013 that develops and commercializes fully synthetic electrospun fiber matrix products for regenerative wound care and soft tissue repair. Its technology platform produces sub-cellular (sub-micron to micron) polymer fibers that are structurally similar to native human extracellular matrix, are free of animal and human components, resist enzymatic degradation, and resorb via hydrolysis at a rate designed to match tissue ingrowth. The product portfolio centers on the Restrata platform (Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix form factors) for wound management and soft tissue reinforcement, alongside Cerafix, a synthetic dural repair matrix for neurosurgical applications. Multiple FDA 510(k) clearances and 38 peer-reviewed clinical publications, including Level I randomized controlled trial evidence, support the products' clinical positioning across surgical specialties including orthopedic trauma, plastic and reconstructive surgery, head and neck, foot and ankle, and wound care.

The company operates a direct field sales go-to-market model, employing Senior Account Executives and Associate Account Executives who engage hospitals, surgical centers, and wound care facilities across multiple US markets. Revenue is generated through one-time hardware sales of FDA-cleared medical devices to healthcare providers, with pricing handled via quote-based B2B contracts rather than public list pricing. Reported clinical outcomes include 96% complete closure rates for acute surgical wounds, 82-89% closure rates for chronic wounds, over 95% average skin graft take rates, and Level I RCT evidence showing 74% complete wound closure in the Restrata group versus 33% in control for diabetic foot ulcers. Following a strategic sale process, Acera was acquired by Solventum Corporation (NYSE: SOLV, spun off from 3M in April 2024) for $725 million in cash plus up to $125 million in contingent milestone payments, with the transaction announced November 2025 and completed December 2025; Acera now operates as a wholly-owned subsidiary of Solventum.

Name

Acera Surgical

Legal name

Acera Surgical, Inc.

Website

https://acera-surgical.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

1–10 employees

Short description

Acera Surgical is a St. Louis-based bioscience company developing fully synthetic electrospun fiber matrix products (Restrata and Cerafix) for regenerative wound care, soft tissue reinforcement, and dural repair, sold directly to hospitals and surgical centers.

Ownership category

akta.pro rank

Product category

Regenerative Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Electrospun fiber matrix
• Regenerative wound care
• Soft tissue repair
• Synthetic surgical materials
• Dural repair devices

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Acera Surgical generates revenue through the sale of its FDA-cleared medical devices including Restrata (Sheet, Meshed, MiniMatrix) and Cerafix. These are one-time use products sold to hospitals and surgical centers for soft tissue repair and wound management procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Acera Surgical designs, manufactures, and sells fully synthetic, electrospun fiber matrix medical devices sold under the Restrata and Cerafix brands. These FDA 510(k)-cleared products are used by surgeons and wound care specialists for management of chronic and acute wounds, treatment of dermal scarring, and surgical soft tissue reinforcement including tendon, peripheral nerve, and dural repair.

Product overview

Acera Surgical is a bioscience company developing and commercializing fully engineered electrospun fiber matrix products for regenerative medicine. The company's core product portfolio centers on the Restrata platform, which includes three distinct form factors: Restrata Sheet (standard electrospun matrix), Restrata Meshed (pre-meshed expandable version), and Restrata MiniMatrix (micronized dispersible form). All Restrata products are fully synthetic, resorbable matrices engineered to be structurally similar to human extracellular matrix (ECM) and are indicated for wound management and soft tissue reinforcement. The company also offers Cerafix, a separate product line for dural repair in neurosurgical applications. Acera's technology is based on patented electrospinning processes that create sub-cellular fibers free of animal and human components.

Differentiator

Problem solved

Functional benefit

Brands

• Restrata: First electrospun fiber matrix for soft tissue repair, including Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix products for wound management and soft tissue reinforcement.
• Cerafix
• Covora

Products and services

• Restrata Sheet Restrata Sheet is a fully synthetic electrospun fiber matrix offered as a sheet form, FDA 510(k)-cleared for management of chronic and acute wounds (including partial and full-thickness wounds), treatment of dermal scarring, and surgical soft tissue reinforcement. It is intended for use by surgeons and wound care specialists across multiple surgical specialties.
• Restrata Meshed Restrata Meshed is a meshed (fenestrated) form variant of the Restrata electrospun fiber matrix, providing the same FDA 510(k)-cleared indications for wound management and soft tissue reinforcement while allowing exudate drainage and improved conformability to irregular wound surfaces.
• Restrata MiniMatrix Restrata MiniMatrix is a small-format electrospun fiber matrix in the Restrata product family, designed for surgical applications requiring a compact matrix such as peripheral nerve and tendon repair, while sharing the same FDA 510(k)-cleared synthetic scaffold technology as the broader Restrata line.
• Cerafix Dural Repair Matrix Cerafix is Acera Surgical's FDA 510(k)-cleared electrospun fiber matrix specifically indicated for use as a dura mater substitute in the repair of the dura mater following neurosurgical procedures. It leverages the same synthetic, enzymatic degradation-resistant electrospun platform as Restrata.

Quantifiable outcome

• 96% complete closure rate for acute surgical wounds (average 3.8 weeks to closure)
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic is a major player in neurosurgery and sells dural repair grafts (e.g., Durepair) and other neurosurgical implants that compete with Acera's Cerafix. Its scale, surgeon relationships, and capital position make it the dominant incumbent in Cerafix's category.
• Coloplast: Coloplast's Wound & Skin Care business sells Biatain, Flaminal, and other advanced wound care dressings into hospitals and home care, overlapping with Acera's wound care call points. Coloplast provides a relevant scale benchmark for commercial reach and reimbursement infrastructure.
• Becton, Dickinson and Company (BD): BD's Medical Surgery segment sells biosurgery and soft tissue repair products (e.g., Avitene, Surgiflo) into the same surgical specialty call points Acera targets. As a broad incumbent, BD exemplifies the strategic-acquirer archetype that valued Acera's differentiated synthetic platform.
• ConvaTec: ConvaTec offers Aquacel and other advanced wound care and skin protection products targeting the same hospitals, wound care clinics, and podiatric call points as Acera. Its broad portfolio and distribution muscle make it a key competitor for formulary placement.
• Stryker: Stryker's Medical/Surgical and Orthopedics & Spine segments overlap with Acera's orthopedic trauma and soft tissue reinforcement use cases. As a diversified medtech incumbent, Stryker represents both a competitor for hospital budgets and a potential acquirer benchmark.
• Baxter International: Baxter's Advanced Surgery business (surgical sealants, haemostats, soft tissue repair products such as Tisseel and Floseal) competes with Restrata in surgical soft tissue reinforcement. Baxter's global hospital salesforce provides a useful comparator for international expansion economics.
• Smith+Nephew: Smith+Nephew's Advanced Wound Management portfolio (e.g., PICO, ALLEVYN, collagen matrices) competes with Restrata in hospital and outpatient wound care. As a much larger diversified medtech player, it sets pricing and formulary benchmarks Acera must match or differentiate against.

Direct peers

• Organogenesis: Organogenesis is a direct competitor in advanced wound care with Apligraf, Dermagraft, and PuraPly, selling into the same hospital wound care and surgical specialty call points Acera targets. Both companies compete on clinical evidence and reimbursement coverage in chronic wound healing.
• MiMedx: MiMedx markets placental tissue allografts (e.g., EpiFix, AmnioFix) for wound care and surgical recovery, overlapping directly with Restrata in chronic wounds and soft tissue repair. MiMedx competes on biological vs synthetic positioning and is sold via the same surgeon-channel dynamics.
• Integra LifeSciences: Integra competes directly with Acera across neurosurgical dural repair (DuraGen, DuraSeal) and regenerative wound care/soft tissue repair (Integra Dermal Regeneration Template). Like Acera, Integra sells through a hospital-focused sales force and relies on specialty surgical adoption, making it the closest like-for-like comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acera Surgical